HUP0002440A2 - Savas lipofil vegyületeket tartalmazó gyógyászati készítmény ön-emulgeáló formában - Google Patents

Savas lipofil vegyületeket tartalmazó gyógyászati készítmény ön-emulgeáló formában

Info

Publication number
HUP0002440A2
HUP0002440A2 HU0002440A HUP0002440A HUP0002440A2 HU P0002440 A2 HUP0002440 A2 HU P0002440A2 HU 0002440 A HU0002440 A HU 0002440A HU P0002440 A HUP0002440 A HU P0002440A HU P0002440 A2 HUP0002440 A2 HU P0002440A2
Authority
HU
Hungary
Prior art keywords
self
preparation
pharmaceutical composition
lipophilic compounds
emulsifying formulation
Prior art date
Application number
HU0002440A
Other languages
English (en)
Inventor
Ping Gao
Walter Morozowich
Original Assignee
Pharmacia & Upjohn Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co. filed Critical Pharmacia & Upjohn Co.
Publication of HUP0002440A2 publication Critical patent/HUP0002440A2/hu
Publication of HUP0002440A3 publication Critical patent/HUP0002440A3/hu
Publication of HU228923B1 publication Critical patent/HU228923B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

A jelen találmány meghatározott mennyiségű bázikus amin alkalmazásánalapuló új gyógyászati készítményre vonatkozik, amely hatóanyagként(II) általános képletű piranon-származékot, a készítmény össztömegéreszámított kb. 0,1-kb. 10 tömeg% mennyiségben valamely bázikus amint,egy vagy több gyógyászatilag elfogadható oldószert és egy vagy többgyógyászatilag elfogadható felületaktív anyagot tartalmaz. Akészítmény ezen kívül egy vagy több gyógyászatilag elfogadható olajatis tartalmazhat. A készítmény önemulgeáló formában van, mely a lipofilpiranon-származékok nagy koncentrációját és nagy mértékű biológiaihozzáférhetőségét biztosítja. Ó
HU0002440A 1997-07-29 1998-07-27 Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation HU228923B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5401297P 1997-07-29 1997-07-29
PCT/US1998/014817 WO1999006044A1 (en) 1997-07-29 1998-07-27 Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation

Publications (3)

Publication Number Publication Date
HUP0002440A2 true HUP0002440A2 (hu) 2001-09-28
HUP0002440A3 HUP0002440A3 (en) 2001-10-29
HU228923B1 HU228923B1 (en) 2013-06-28

Family

ID=21988155

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002440A HU228923B1 (en) 1997-07-29 1998-07-27 Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation

Country Status (25)

Country Link
US (1) US6231887B1 (hu)
EP (1) EP0989851B1 (hu)
JP (1) JP4524367B2 (hu)
KR (1) KR100509131B1 (hu)
CN (1) CN1112927C (hu)
AT (1) ATE225174T1 (hu)
AU (1) AU728626B2 (hu)
BR (1) BR9810729B1 (hu)
CA (1) CA2294033C (hu)
CY (1) CY2006002I2 (hu)
CZ (1) CZ296957B6 (hu)
DE (1) DE69808463T2 (hu)
DK (1) DK0989851T3 (hu)
ES (1) ES2184310T3 (hu)
FI (1) FI20000172A (hu)
HK (1) HK1028879A1 (hu)
HU (1) HU228923B1 (hu)
NO (1) NO323425B1 (hu)
NZ (1) NZ502566A (hu)
PL (1) PL192865B1 (hu)
PT (1) PT989851E (hu)
RU (1) RU2202346C2 (hu)
SI (1) SI0989851T1 (hu)
SK (1) SK284616B6 (hu)
WO (1) WO1999006044A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
ES2234582T3 (es) * 1999-03-31 2005-07-01 PHARMACIA & UPJOHN COMPANY LLC Emulsiones farmaceuticas para inhibidores de proteasas retrovirales.
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CN1240437C (zh) * 2000-10-31 2006-02-08 贝林格尔·英格海姆药物公司 口服的自乳化的吡喃酮蛋白酶抑制剂制剂
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
BR0307344A (pt) * 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US7157424B2 (en) * 2003-04-02 2007-01-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US7943670B2 (en) * 2003-10-07 2011-05-17 Eli Lilly And Company Liquid formulations of ractopamine
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
EP1814548A1 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
EP1819348A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
JP5028885B2 (ja) * 2006-07-04 2012-09-19 大正製薬株式会社 ユビデカレノン含有自己乳化組成物
JP5448854B2 (ja) 2007-03-12 2014-03-19 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−プロテアーゼ阻害剤複合体
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
PT2451438E (pt) 2009-07-07 2014-03-26 Boehringer Ingelheim Int Composição farmacêutica para um inibidor de protease viral da hepatite c
JP5951489B2 (ja) 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組成物
RU2419426C1 (ru) * 2010-04-26 2011-05-27 Всеволод Иванович Киселев Лекарственное средство на основе дииндолилметана (dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
MX341082B (es) 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
SG11201505245XA (en) * 2013-01-14 2015-08-28 Infirst Healthcare Ltd Compositions and methods for treating severe pain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
DE3300793A1 (de) * 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
GB8903804D0 (en) 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
JPH10504291A (ja) * 1994-07-22 1998-04-28 ジー．ディー．サール アンド カンパニー 自己乳化性ドラッグデリバリーシステム
AU692255B2 (en) * 1995-04-24 1998-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
ATE226075T1 (de) 1995-06-06 2002-11-15 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen inhibitor von proteinase und einen monoglycerid
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
BR9810729A (pt) 2000-08-08
US6231887B1 (en) 2001-05-15
CA2294033C (en) 2007-01-09
SK162000A3 (en) 2000-12-11
AU728626B2 (en) 2001-01-11
CZ296957B6 (cs) 2006-08-16
NZ502566A (en) 2002-03-28
PL192865B1 (pl) 2006-12-29
NO20000466D0 (no) 2000-01-28
DE69808463T2 (de) 2003-06-26
CY2006002I2 (el) 2012-01-25
SI0989851T1 (en) 2003-04-30
ES2184310T3 (es) 2003-04-01
WO1999006044A1 (en) 1999-02-11
HUP0002440A3 (en) 2001-10-29
KR20010022369A (ko) 2001-03-15
CA2294033A1 (en) 1999-02-11
ATE225174T1 (de) 2002-10-15
SK284616B6 (sk) 2005-07-01
EP0989851A1 (en) 2000-04-05
JP2002510330A (ja) 2002-04-02
NO20000466L (no) 2000-03-28
DE69808463D1 (de) 2002-11-07
PL338335A1 (en) 2000-10-23
DK0989851T3 (da) 2003-01-27
RU2202346C2 (ru) 2003-04-20
CY2006002I1 (el) 2011-02-02
NO323425B1 (no) 2007-04-30
PT989851E (pt) 2002-12-31
HK1028879A1 (en) 2001-03-09
CZ2000156A3 (cs) 2000-05-17
FI20000172A (fi) 2000-01-28
AU8573898A (en) 1999-02-22
CN1112927C (zh) 2003-07-02
JP4524367B2 (ja) 2010-08-18
KR100509131B1 (ko) 2005-08-18
EP0989851B1 (en) 2002-10-02
HU228923B1 (en) 2013-06-28
CN1261796A (zh) 2000-08-02
BR9810729B1 (pt) 2010-07-13

Similar Documents

Publication Publication Date Title
HUP0002440A2 (hu) Savas lipofil vegyületeket tartalmazó gyógyászati készítmény ön-emulgeáló formában
HUP9901710A2 (hu) Új stabil gyógyszerkompozíciók hajtógáztól mentes aeroszolok képzésére
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
IL149163A0 (en) Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them
EP0882450A3 (en) Cholesterol-lowering composition comprising coenzyme Q
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
NO954072D0 (no) Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
DE69635996D1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
RU94046044A (ru) Новые 7 бета -замещенные 4-аза- 5 альфа -холестан-оны в качестве ингибиторов 5 альфа -редуктазы, фармацевтическая композиция на их основе, способ ее получения
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
HUP0301487A2 (hu) Piranon proteáz inhibitorok orális adagolású önemulgeáló formulációi
HUP0004701A2 (hu) Új dezloratadin sók, az ezeket tartalmazó gyógyászati készítmények és eljárás azok előállítására
PT911026E (pt) Derivados da creatina para a asma
HUP0301334A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és taxánokat és/vagy antimetabolitokat tartalmazó kombinált tumorellenes kompozíciók
NO950177D0 (no) Farmakologisk aktive erivater
HUP0300929A2 (hu) Fájdalomcsillapító és/vagy izomrelaxáns hatású gyógyászati készítmény
ATE298564T1 (de) Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel
ECSP055804A (es) Composición farmacéutica
DE60003328D1 (de) Ruthenium (ii) komplexe mit hoher antitumor und antimetastatischer wirkung
DE69318418T2 (de) Pharmazeutische zusammensetzungen, die 5-ht 1-rezeptoragonisten und absorptionsverstärker enthalten
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"